Active, not recruitingPhase 2NCT07185776
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Studying Disorder of lipid absorption and transport
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Intervention
- HRS-5632 Injection(drug)
- Enrollment
- 203 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- The Second Affiliated Hospital of AFMU, Xi’an, Shanxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07185776 on ClinicalTrials.govOther trials for Disorder of lipid absorption and transport
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07235046A Study of DII235 in Adults With Elevated Lipoprotein(a)Novartis Pharmaceuticals
- RECRUITINGPHASE2NCT07327840Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)Kylonova (Xiamen) Biopharma co., LTD.
- RECRUITINGNCT07324902The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial DeformationUniversity of Athens
- ACTIVE NOT RECRUITINGNCT04156997Extreme Lipids RepositoryUniversity of Texas Southwestern Medical Center
See all trials for Disorder of lipid absorption and transport →